MX2010010235A - Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina. - Google Patents

Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.

Info

Publication number
MX2010010235A
MX2010010235A MX2010010235A MX2010010235A MX2010010235A MX 2010010235 A MX2010010235 A MX 2010010235A MX 2010010235 A MX2010010235 A MX 2010010235A MX 2010010235 A MX2010010235 A MX 2010010235A MX 2010010235 A MX2010010235 A MX 2010010235A
Authority
MX
Mexico
Prior art keywords
indolobenzadiazepine
hcv ns5b
ns5b inhibitors
pyrrolidine fused
pyrrolidine
Prior art date
Application number
MX2010010235A
Other languages
English (en)
Inventor
John F Kadow
John A Bender
Zhong Yang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2010010235A publication Critical patent/MX2010010235A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona compuestos de la fórmula (I), (ver fórmulas (I)) incluyendo sus sales, así como composiciones y métodos para usar los compuestos. Los compuestos tienen actividad contra virus de la hepatitis C (HCV) y pueden ser útiles para tratar a aquellos infectados con HCV.
MX2010010235A 2008-03-27 2009-03-25 Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina. MX2010010235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3997308P 2008-03-27 2008-03-27
PCT/US2009/038167 WO2009120733A1 (en) 2008-03-27 2009-03-25 Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
MX2010010235A true MX2010010235A (es) 2010-10-05

Family

ID=40791440

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010235A MX2010010235A (es) 2008-03-27 2009-03-25 Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.

Country Status (8)

Country Link
US (1) US8119628B2 (es)
EP (1) EP2280978B1 (es)
JP (1) JP2011515484A (es)
KR (1) KR20100126560A (es)
CN (1) CN102046630A (es)
ES (1) ES2416062T3 (es)
MX (1) MX2010010235A (es)
WO (1) WO2009120733A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515486A (ja) 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の治療用化合物
CN102712643B (zh) 2009-05-22 2015-12-16 Abbvie公司 5-ht受体的调节剂及其使用方法
KR101799272B1 (ko) 2010-02-03 2017-11-20 엘지전자 주식회사 무선 통신 시스템에서 제어 정보의 전송 방법 및 장치
WO2011146089A1 (en) 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
CN102924462B (zh) * 2012-10-24 2015-01-14 华东师范大学 1,2,3,4,5,9-取代苯并吖庚因类化合物的合成方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1807397A2 (en) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
CN101918410B (zh) 2007-11-20 2013-02-27 百时美施贵宝公司 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
JP2011515486A (ja) 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の治療用化合物
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
US20110020276A1 (en) 2011-01-27
JP2011515484A (ja) 2011-05-19
ES2416062T3 (es) 2013-07-30
EP2280978A1 (en) 2011-02-09
AU2009228325A1 (en) 2009-10-01
US8119628B2 (en) 2012-02-21
WO2009120733A1 (en) 2009-10-01
KR20100126560A (ko) 2010-12-01
EP2280978B1 (en) 2013-04-24
CN102046630A (zh) 2011-05-04

Similar Documents

Publication Publication Date Title
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
SI1987038T1 (sl) Hcv ns5b inhibitorji
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
MX2010005226A (es) Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
EA201100390A1 (ru) Соединения для лечения гепатита с
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
NO20090453L (no) Hepatitt C Virusinhibitorer
MX337050B (es) Compuestos 4'-azido-nucleósidos como anti-vhc.
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c

Legal Events

Date Code Title Description
FG Grant or registration